← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-7 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodystaleRochePhase 3

High-dose Epirubicin Combined with CVP ± Rituximab (High-dose Epirubicin Combined with CVP ± Rituximab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleWeill Medical College of Cornel…Phase 3

Higher Dose of Rituximab (Higher Dose of Rituximab)

Immune Thrombocytopenic Purpura · Immune Thrombocytopenic Purpura

#ImmuneThrombocytopenicPurpura#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 3

adalimumab (Humira, Human anti-TNF monoclonal antibody/adalimumab)

Psoriatic Arthritis · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 1

adalimumab-EU (Humira, Humira (adalimumab-EU))

Healthy · Healthy

#Healthy#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 1

adalimumab-US (Humira, Humira (adalimumab-US))

Healthy · Healthy

#Healthy#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbViePhase 1

adalimumab (Humira, Humira®, Humira® (adalimumab) AC Pen [Reference Product])

Pharmacokinetics; Safety Issues · Pharmacokinetics

#Pharmacokinetics#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleShanghai Pulmonary Hospital, Sh…Phase 2

IBI310+Sintilimab (IBI310+Sintilimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBiogenPhase 2

rituximab (IDEC-C2B8, IDEC-C2B8 (rituximab))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 + nivolumab)

Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 and nivolumab)

Urothelial Carcinoma; Urothelial Carcinoma Bladder · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodyBiologicstaleSecond Affiliated Hospital, Sch…Approved

IL-17A/F mAb + NAFL (IL-17A/F mAb + NAFL)

Hidradenitis Suppurativa (HS) · Hidradenitis Suppurativa (HS)

#HidradenitisSuppurativaHS#Antibody#Approved#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleGregory DanielsPhase 2

nivolumab (Opdivo, IL-2 and Nivolumab)

Melanoma Stage Iv; Renal Cell Carcinoma, Metastatic · Melanoma Stage Iv

#MelanomaStageIv#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 DISCONTINUED
AntibodystaleImmuneering CorporationPhase 2

Treatment Group E (IMM-1-104 + pembrolizumab, IMM-1-104 + pembrolizumab (Treatment Group E))

Advanced Solid Tumor; Pancreatic Adenocarcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAssociazione Volontari Pazienti…Phase 3

INDUCTION CTx (TPF, INDUCTION CTx, INDUCTION CTx(TPF)+(RT+CETUXIMAB))

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAstraZenecaPhase 1

durvalumab (Imfinzi, IPH5401 and Durvalumab)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleUniversity of Colorado, DenverPhase 1

IPI-926 and Cetuximab (IPI-926 and Cetuximab)

Recurrent Head and Neck Cancer · Recurrent Head and Neck Cancer

#RecurrentHeadandNeckCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleChristian BuskePhase 2

Ibrutinib / Bortezomib / Rituximab (Ibrutinib / Bortezomib / Rituximab)

Waldenstrom Macroglobulinemia · Waldenstrom Macroglobulinemia

#WaldenstromMacroglobulinemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleChinese Academy of Medical Scie…Phase 2

Ibrutinib Combined With Rituximab (Ibrutinib Combined With Rituximab)

DLBCL; MYD88 Gene Mutation · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleMerckPreclinical

pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab (Immune Checkpoint Inhibitors, Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab))

Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Squamous Cell Carcinoma (ESCC

#EsophagealSquamousCellCarcinomaE#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING

34 / 62 페이지

← 이전다음 →